Form DEFA14A JANUS INVESTMENT FUND
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☒ | Soliciting Material under §240.14a-12 |
Janus Investment Fund
(Name of Registrant as Specified in Its Charters)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials: |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
U.S. Mutual Fund & ETF Shareholders: Your Vote Matters As Janus Henderson moves toward closing its take private transaction with Trian and General Catalyst, U.S. mutual fund and ETF shareholders are being asked to vote on a new investment advisory agreement. This vote is a required step due to a change in ownership—not a change in investment teams, processes, or how portfolios are managed. The Boards of Trustees recommends shareholders vote FOR approval, which will allow Janus Henderson to continue serving as investment adviser to the funds following the transaction’s close. Clients can vote quickly and easily: Online – Mutual Funds: www.votejhi.com/mutualfunds – ETFs: www.votejhi.com/ETFs By phone (live agent) – Mutual Funds: +1-855-206-2338 – ETFs: +1-855-206-2309 By mail using their proxy card We appreciate your continued partnership. #clientscomefirstalways #togetherwewin Platform LinkedIn
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IMA ART's Fertility Family Office - Swiss Governance for Family Continuity
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- Salomon Unfolds the Next Chapter of ROAD TO THE FUTURE in Shanghai
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share